Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR211: a peripheral CB1 receptor antagonist”(2018/12/17)


NHRI technology, “DBPR211: a peripheral CB1 receptor antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing.


Cannabinoid receptor 1 (CB1) is expressed in several peripheral tissues related to metabolic control and its dysregulation contributes to metabolic disorders. DBPR211 is a highly selective antagonist of peripheral CB1 receptors. It exhibits beneficial effects in treating insulin resistance​, obesity and non-alcoholic fatty liver disease. This unique mechanism may potentially render DBPR211 as a highly competitive first-in-class drug candidate for the treatment of type 2 diabetes, obesity and non-alcoholic fatty liver disease.

Potential collaboration partner qualifications:

  1. be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
  2. better to have related experience and skills for developing The Technology
  3. better to have experience of international collaboration and clinical trial
  4. be willing to provide long-term investment


Please contact to Mr. Hua-Hsuan Liang (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206, E-mail:


If The Technology has been exclusively licensed, this announcement will automatically invalid. For detailed status of The Technology, please contact to the case officer.


I: Announcement

II: Licensing Proposal

III: Industry-Academia Collaboration Proposal